In short
Galcanezumab, also known by the brand name Emgality, is a calcitonin gene-related peptide (CGRP) antagonist that has shown promise in clinical trials for the prevention and treatment of migraine. This article summarizes key findings from various clinical trials investigating the efficacy, safety, and tolerability of galcanezumab in patients with episodic and chronic migraine, as well as its potential applications for other conditions like cluster headache and neuropathic pain.
At a glance
- Drug Name
- Galcanezumab (Brand name: Emgality)
- Drug Class
- Calcitonin Gene-Related Peptide (CGRP) Antagonist
- Primary Use
- Prevention of migraine in adults
- Administration
- Subcutaneous injection, typically 240mg loading dose followed by 120mg monthly
- Efficacy
- Reduction in monthly migraine days, improved quality of life, decreased use of acute medications
- Safety Profile
- Generally well-tolerated; common side effects include injection site reactions, constipation, dizziness
- Special Populations
- Limited data in pregnancy and breastfeeding; studies ongoing
- Other Potential Uses
- Episodic cluster headache, treatment-resistant migraine, neuropathic pain (under investigation)
What is Galcanezumab?
Galcanezumab, also known by the brand name Emgality, is a medication used for the prevention of migraine headaches in adults. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) antagonists, which work by blocking a protein involved in migraine pain.
How Does It Work?
Galcanezumab works by targeting and blocking a protein called CGRP. This protein is believed to play a key role in causing migraine pain. By blocking CGRP, galcanezumab can help prevent migraine attacks from occurring. This mechanism of action makes it different from many other migraine prevention medications that work on other pathways in the brain.
What Conditions Does Galcanezumab Treat?
Galcanezumab is primarily used to treat and prevent: Episodic migraine: This refers to having migraine headaches on fewer than 15 days per month. Chronic migraine: This is defined as having headaches on 15 or more days per month, with at least 8 of those days involving migraine symptoms. Cluster headache: Some studies have also investigated the use of galcanezumab for both episodic and chronic cluster headaches, which are severe headaches that occur in cyclical patterns.
How is Galcanezumab Administered?
Galcanezumab is given as a subcutaneous (under the skin) injection. Typically, the treatment regimen involves: An initial loading dose of 240 mg (two 120 mg injections) Followed by monthly doses of 120 mg The medication can be self-administered at home using either an auto-injector or a pre-filled syringe.
Effectiveness of Galcanezumab
Clinical trials have shown that galcanezumab can be effective in reducing the number of migraine days per month. Some key findings include: Reduction in monthly migraine days: Many patients experience a significant decrease in the number of days they have migraines each month. Improved quality of life: Patients often report improvements in their ability to function in daily life and work. Decreased use of acute migraine medications: Many patients find they need to use fewer medications to treat acute migraine attacks.
Potential Side Effects
Like all medications, galcanezumab can cause side effects. The most commonly reported side effects include: Injection site reactions (such as pain, redness, or swelling at the injection site) Constipation Itching Rash Serious side effects are rare, but can include allergic reactions. It's important to discuss any side effects with your healthcare provider.
Use in Special Populations
Research is ongoing to understand the safety and effectiveness of galcanezumab in various populations: Adolescents: Studies are being conducted to evaluate the use of galcanezumab in patients aged 12 to 17 years with chronic migraine. Pregnant and breastfeeding women: Research is being done to understand how galcanezumab may affect breast milk and infant outcomes. Treatment-resistant migraine: Some studies focus on patients who haven't responded well to other migraine prevention treatments.
Ongoing Research
Scientists continue to study galcanezumab to better understand its long-term effects, optimal dosing, and potential use in other conditions. Some areas of ongoing research include: Use in combination with other migraine treatments Effectiveness in different types of headache disorders, such as cluster headaches Potential use in other pain conditions, such as trigeminal neuralgia